ZYTIGA Receives FDA Approval For Label Update For Prolonged Survival In Metastic Castration-Resistant Prostate Cancer

ZYTIGA Receives FDA Approval For Label Update For Prolonged Survival In Metastic Castration-Resistant Prostate Cancer
ZYTIGA received approval from the U.S. Food and Drug Administration (FDA) for a label update on March 30, 2015. The approval was based on the results of a Phase 3 clinical study showing the drug could prolong median overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC). ZYTIGA was approved in the U.S. in 2011,

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *